Clinical trial Recruiting at 1 site Observational Ages 18 to 90

Tracking delayed ischemic neurological deficits in people with aneurysmal subarachnoid hemorrhage — real-world data

Official title: Delayed Ischemic Neurological Deficit in Patients With Aneurysmal Subarachnoid Hemorrhage: Real World Study (DINDaSAH)

Run by Xuanwu Hospital, Beijing · NCT07160088 · Data updated 2026-11-12

This project will collect real-world monitoring and treatment information to see how often delayed ischemic neurological deficits (DIND) happen and what diagnostic and treatment approaches people with aneurysmal subarachnoid hemorrhage receive.

Quick facts

Study typeObservational
Ages18 Years to 90 Years
SexAll
Enrollment10000 (estimated)
SponsorXuanwu Hospital, Beijing
Academic / other
Locations1 site (Beijing, Beijing Municipality)
StatusRecruiting
StartedSeptember 3, 2025
Main results expectedDecember 31, 2027
Study endsDecember 31, 2027
Registry record updatedJanuary 2, 2026
Trial IDNCT07160088 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18 or older admitted to the ICU with aneurysmal subarachnoid hemorrhage confirmed by cerebral CT angiography or cerebral vessel angiography who can provide informed consent.

Probably not a fit

People with subarachnoid hemorrhage not caused by a ruptured cerebral aneurysm (for example traumatic SAH, AVM-related, or tumor-related bleeding) are not eligible and would not benefit from this project.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, multicenter observational effort enrolling adults admitted to the ICU with aneurysmal subarachnoid hemorrhage. It will record neurological exam findings, instrument monitoring changes, diagnostic methods, and the treatments used when delayed ischemic neurological deficits occur. The study will describe the incidence of DIND and compare real-world diagnostic and treatment patterns across centers. No investigational interventions are assigned and patient care follows local clinical practice.

Why it matters

Potential benefit: If successful, the findings could help clinicians detect DIND earlier and guide more consistent diagnostic and treatment approaches, potentially reducing longer-term neurological disability.

How similar studies have gone: Previous observational registries have described symptomatic vasospasm and delayed cerebral ischemia but no single diagnostic gold standard or unified treatment guideline exists, so this real-world data collection follows precedent while addressing remaining gaps.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Age ≥ 18 years old
2. Primary diagnosis of subarachnoid hemorrhage due to rupture of a cerebral artery aneurysm confirmed by cerebral angiotomography or intracranial vessel angiography, requiring admission to the Intensive Care Unit (ICU).
3. Signature of the Informed Consent Form for participation in the study in accordance with local applicable regulations.

Exclusion Criteria:

1. Age \< 18 years old
2. Primary diagnosis of subarachnoid hemorrhage withouth a visible aneurysm, i.e., post-traumatic or caused by an arteriovenous malformation or bleeding from a brain tumor.

Where it's running

  • Department of neurosurgery, Xuanwu hospital, Capital Medical University
    Beijing, Beijing Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.